Moreover, we confirmed the efficiency of the PPAR-γ antagonist GW9662 (1 mg/kg) to significantly decrease PPAR-γ levels compared to GBM mice (Figure 7G, see densitometric analysis panel G1). Here, PPARG is linked to glioblastoma.